Multi-target combination therapies could be applied in GC treatment, for example, TGF-β blockers in combination with PD-1/PD-L1 inhibitors, or sequential therapies, such as blocking TGF-β or IL-6 first to release the immunosuppressive microenvironment, followed by the administration of immune checkpoint inhibitors. Here, TGFB1 is linked to gastric cancer.